ZTS · Zoetis Inc
Price
Snapshot
50 fields · last close| Market Cap | $31.87B |
| P/E | 12.55 |
| Float | 418.6M |
| Beta | 0.70 |
| Volatility | 17.5% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 77.1 |
| Price | 79.61 |
| Change | +0.29% |
| Prev Close | 79.38 |
| Open | 78.29 |
| Day Low | 78.29 |
| Day High | 80.59 |
| Avg Vol | 4 |
| Avg $ Vol | $336.8M |
| 52W High | 148.30 |
| 52W Low | 68.77 |
| 52W Pos | 13.6% |
| From High | −46.32% |
| From Low | +15.76% |
| Max DD 1Y | −53.16% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +9.60% |
| SMA 50 | +7.60% |
| SMA 200 | −16.96% |
| RSI (14) | 69.4 |
| Vol 30D | 25.3% |
| Vol 90D | 30.5% |
| 1Y Range | 69–148 |
| Daily bars | 536 |
| Perf Week | +6.11% |
| Perf Month | +8.71% |
| Perf Quarter | +4.17% |
| Perf Half Y | −35.14% |
| Perf Year | −44.15% |
| Perf YTD | −36.78% |
| Prev Day | +0.29% |
| Clavix | B+ |
| Debt / Eq | 2.72 |
| Curr Ratio | 3.03 |
| Int Cover | 12.7× |
| FCF Margin | 24.1% |
| Rev Growth | +2.3% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 7 / 14 |
What ZTS does
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Clavix risk grade
regraded every trading dayZTS grades B+, 77.1 of 100. Steadiest on Macro Resilience (67), most exposed on News Sentiment (57, mixed). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 7 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| ZTS | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.70 | 0.44 |
| Volatilityannualized | 17.5% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −53.2% | — |
| Typical daily movemedian absolute daily change | 1.01% | — |
| Days beyond ±3%of the last 252 sessions | 26 (10%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ZTS | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.70 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ZTS | |
|---|---|
| 1 week | +6.1% |
| 1 month | +8.7% |
| Year to date | −36.8% |
| 1 year | −44.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ZTS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Aug |
| Average score0 most bearish, 100 most bullish | 54 |
| Bullish · bearisharticles above 60 · below 40 | 14 · 7 |
| Directionarticles whose tone is improving vs worsening | 14 ↑ 7 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| ZTS | |
|---|---|
| Revenue growthyear over year | +2.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGoldman Sachs changed its rating on Zoetis (ZTS) stock to 'hold' in a report issued on Friday. No other details or reasons were provided in the article.
Zoetis announced the appointment of Iris Knobloch to its Board of Directors, effective December 1, 2026. Knobloch currently serves on the boards of Deezer, Lazard, and Vail Resorts, and is President of the Festival de Cannes.
Zoetis announced the appointment of Iris Knobloch to its Board of Directors, effective December 1, 2026. The company highlighted her decades of experience in global media and consumer businesses, international leadership, public company board experience, and consumer and digital expertise.
Zoetis announced the appointment of Iris Knobloch to its Board of Directors, effective December 1, 2026. She brings experience in global media, public company board roles across financial services, hospitality and media, and consumer and digital expertise.
It notes the share price is down 60.9% over the past 5 years and questions whether the current valuation is supported by the company's earnings, but does not cite any specific Q2 results or developments.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.65B | 14.51 | 0.38 | Compare |
| CORT | Corcept Therapeutics Inc | C | $11.91B | 215.80 | 0.52 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.77B | — | 1.74 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $122.1B | 13.15 | 0.19 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $8.23B | — | 0.82 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.